News Tag: Matt Tremblay

Repurposed cancer drug highlights potential for innovative diabetes treatment

A study led by Calibr scientists reveals that an FDA-approved cancer therapy can protect insulin-producing beta cells.  

A well-known animal health drug could stop outbreaks of malaria and Zika virus

The researchers estimated that a single human dose of the drugs would convey an insecticide effect against mosquitos and sand flies lasting 50–90 days.

Calibr and TSRI Executive Matt Tremblay Receives Biocom Catalyst Award

"Matt’s scientific contributions and business leadership played an important role in establishing Calibr and creating the new model for translational research and innovation represented by the affiliation with TSRI."